Companies · Biotechnology

Liquid Genomics, Inc.

TORRANCE · Biotechnology

Diligence memoA one-page analyst read on Liquid Genomics, Inc. — recommendation, valuation, rhythm, risks.
$4.9M
Total raised · real
2
Rounds
0.5×
Latest step-up
Top 58%
Sector rank · raised
Seed
Latest stage · inferred · Mon Jun 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Liquid Genomics, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.02× the median modeled value of Seed Biotechnology companies in 2016–2018 (175 peers) — value vs value, same stage and era.
  • Within the normal band (102% of peer median) for its niche.
Dormant
  • Last raise 10.0 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Liquid Genomics, Inc. is one of 4291 Biotechnology companies tracked from TORRANCE. By capital raised it ranks mid-pack (ahead of 43% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

biotech

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
13
Investors (latest)
2013
Year incorporated
2016-06-13
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2014-05-20 Raised $3.2M (real) Modeled valuation $144M (est)$3.2M$144MSeed2014Seed · 2016-06-13 Raised $1.6M (real) Modeled valuation $72M (est)$1.6M$72MSeed2016+$1.6MCumulative $4.9M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$3.2M · 2014
Seed extension$1.6M · 2016

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$72.3M
Base estimate est.
$1.2M
Conservative case
$566.9M
Upside case
$8.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $143.7M · 2014-05-202014Seed · modeled $72.3M · 2016-06-132016
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
6.0 yr
Elapsed time used
10.1 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
25 mo
Avg between rounds
$2.4M/yr
Capital velocity
12.1 yr
On record since
2014
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.7× of median
This company$4.9M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.9× of median
This company$1.6M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 1.1× above median
This company$72.3M
Sector median$64.2M

Raised more than 43% of sector peers (real $). Modeled value above 52% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #86 of 175.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0MCapital raised (log)Kenjockety Biotechnology, LLC · Seed Raised $4.0M · modeled $177.6M (est)Mimedx Group, Inc. · Seed Raised $8.2M · modeled $177.6M (est)Helocyte, Inc. · Seed Raised $4.0M · modeled $177.5M (est)CytoDel, INC. · Seed Raised $4.1M · modeled $173.4M (est)Finch Therapeutics, Inc. · Seed Raised $4.5M · modeled $165.8M (est)Cordex Systems, Inc · Seed Raised $6.4M · modeled $164.2M (est)Viking Therapeutics, Inc. · Seed Raised $3.7M · modeled $162.3M (est)Escalier Biosciences B.V. · Seed Raised $3.5M · modeled $155.4M (est)Corino Therapeutics, Inc. · Seed Raised $3.5M · modeled $154.3M (est)BluDiagnostics, Inc. · Seed Raised $4.5M · modeled $151.0M (est)Captozyme Inc. · Seed Raised $3.4M · modeled $151.0M (est)FORGE Life Science, LLC · Seed Raised $3.6M · modeled $149.5M (est)Liquid Genomics, Inc. (this company) Raised $4.9M · modeled $72.3M (est)Liquid Genomics, Inc.
CompanyStageRaised · realValue · estvs peer med.
Kenjockety Biotechnology, LLCSeed$4.0M$177.6M2.50×
Mimedx Group, Inc.Seed$8.2M$177.6M2.50×
Helocyte, Inc.Seed$4.0M$177.5M2.50×
CytoDel, INC.Seed$4.1M$173.4M2.44×
Finch Therapeutics, Inc.Seed$4.5M$165.8M2.33×
Cordex Systems, IncSeed$6.4M$164.2M2.31×
Viking Therapeutics, Inc.Seed$3.7M$162.3M2.28×
Escalier Biosciences B.V.Seed$3.5M$155.4M2.19×
Corino Therapeutics, Inc.Seed$3.5M$154.3M2.17×
BluDiagnostics, Inc.Seed$4.5M$151.0M2.12×
Captozyme Inc.Seed$3.4M$151.0M2.12×
FORGE Life Science, LLCSeed$3.6M$149.5M2.10×
Liquid Genomics, Inc. this companySeed$4.9M$72.3M1.02×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$3.2M2014-05-20$16.2M$143.7M85%
Seed$1.6M2016-06-13$8.1M$72.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$3.2M2014-05-20
    • First recorded raise — entered as Seed.
    • 5 investors on this round.
  2. Seed$1.6M2016-06-13
    • Raised again after 25 mo — slower than the ~14 mo sector norm.
    • Round 2.0× smaller than the prior — bridge or down round.
    • 13 investors on this round.
Intelligence
2018 ~Q3
Modeled next raise · ~25mo cadence
$1.6M
Modeled next size est.range $1.6M$2.6M
0.5×
Last step-up
$2.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Amy Wang4 other2014-05
Eric Huang2 other2014-05
Malcolm MacLean IV1 other2016-06
George Yang2014-05
Gilbert Samberg2016-06
Jinliang Li2014-05
Kathleen Danenberg2014-05
Raj Maheshwari2014-05
Registry & provenance

Liquid Genomics, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1609810
SEC CIK
2013
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Enspire Bio, Inc.BiotechnologySeed$3.2M$143.6Mnetwork1 shared operator · same sector · same stage
Innara Health, Inc.BiotechnologySeed$4.8M$66.3Msame sector · same stage
Spinal Singularity, Inc.BiotechnologySeed$4.9M$88.6Msame sector · same stage
Sollis Therapeutics IncBiotechnologySeed$5.0M$78.4Msame sector · same stage
Lowell Therapeutics, IncBiotechnologySeed$5.0M$86.8Msame sector · same stage
Aevumed Inc.BiotechnologySeed$5.1M$58.9Msame sector · same stage
Panorama Medicine, Inc.BiotechnologySeed$4.7M$65.7Msame sector · same stage
Pediatric Bioscience, Inc.BiotechnologySeed$5.1M$74.5Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Liquid BioScience, Inc.BiotechnologySeries B$1.6B94%
Liquidia Technologies IncBiotechnologySeries B$890.0M89%
Liquidia CorpBiotechnologySeries B$616.1M89%
Trace Genomics, Inc.BiotechSeries B$184.6M86%
Medicinal Genomics CorpBiotechnologySeries A$76.2M86%
BioMedomics, Inc.BiotechnologyPre-Seed$29.3M85%
General Genomics Inc.BiotechSeed$14.1M85%
Inform Genomics, Inc.BiotechnologySeries A$52.5M85%
Frequently asked
How much funding has Liquid Genomics, Inc. raised?
Liquid Genomics, Inc. has raised approximately $4.9M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Liquid Genomics, Inc.'s estimated valuation?
Provath's modeled valuation for Liquid Genomics, Inc. is approximately $72.3M (modeled range $1.2M–$566.9M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Liquid Genomics, Inc. at?
Liquid Genomics, Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Mon Jun 13.
What does Liquid Genomics, Inc. do and where is it based?
Liquid Genomics, Inc. operates in the Biotechnology sector, based in TORRANCE.
Explore related

See where Liquid Genomics, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Liquid Genomics, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.